day 1 agenda
| 6th Edition of Innovations and State of the Art in ALZHEIMER'S & DEMENTIA at Oct 01 - 02, 2025 at Berlin, Germany (Hybrid Event) |
|
| Day -1(October 01, 2025) | |
| Tentative Program | |
| 09:00-09:30 | KeynoteTalk: Genistein (4′,5,7-trihydroxyisoflavone) corrects behavior and improves biochemical parameters in animal models of Alzheimer's disease through autophagy stimulation |
| Grzegorz W?grzyn, University of Gdansk, Poland | |
| 09:30-10:00 | KeynoteTalk: Alzheimer’s disease is likely a lipid-disorder complication as revealed by functional lipidomics and animal models |
| Xianlin Han, University of Texas Health Science Center at San Antonia, USA | |
| 10:00-10:30 | KeynoteTalk: Neurogenesis And Plasticity Processes Are Similarly Affected And Damaged In Alzheimer´s Disease |
| José Julio Rodríguez Arellano, IKERBASQUE, Basque Foundation for Science, Spain | |
| Group Photo & Refreshment Break (10:30-10:50) | |
| Technical session-I | |
| Session Chair: Grzegorz W?grzyn, |
|
| 10:50-11:10 | Changes in expression of VGF, SPECC1L, HLA-DRA and RANBP3L act with APOE E4 to alter risk for late onset Alzheimer’s disease |
| Amanda J. Myers, University of Miami Miller School of Medicine, USA | |
| 11:10-11:30 | TBA |
| 11:30-11:50 | The Alzheimer's Pathobiome Initiative: Using multiple global pan-domain and omic technologies to interrogate the link between infection and dementia |
| Garth D. Ehrlich, Drexel University College of Medicine, USA | |
| 11:50-12:10 | Implications for the Down Syndrome Community of Availability of Anti-Amyloid Alzheimer’s Drug Treatments |
| Matthew P. Janicki, University of Illinois Chicago, USA | |
| 12:10-12:30 | Biological prognosis toolbox for Alzheimer’s disease and other cognitive neurodegenerative diseases |
| Marc Teichmann, Pitié-Salpêtrière University Hospital, France | |
| 12:30-12:50 | Efficacy monitoring using amyloid and tau PET neuroimaging in Down syndrome populations |
| Bradley T. Christian, University of Wisconsin-Madison, USA | |
| 12:50-13:10 | Cerebral Proteome Adaptations to Amyloid Angiopathy are Prevented by Carbonic Anhydrase Inhibitors |
| Johan Magnus Palmfeldt, Aarhus University, Denmark | |
| Lunch Break @ Restaurant (13:10-14:00) | |
| 14:00-14:20 | Blocking FSH action improves memory in mouse models of Alzheimer’s disease |
| Tony Yuen, Icahn School of Medicine at Mount Sinai, USA | |
| 14:20-14:40 | Integrative Multi-Omics Analysis of APOE Genotype-Dependent Molecular Signatures in Alzheimer’s Disease |
| Gyungah R Jun, Boston University School Of Medicine, USA | |
| 14:40-15:00 | Three scenarios for amyloid transformation |
| Irena K. Roterman, Jagiellonian University – Medical College , Poland | |
| 15:00-15:20 | Cerebral Capillopathy Nexus of Neurodegenerative disease |
| Charles R Joseph, Liberty University College of Osteopathic Medicine, USA | |
| 15:20-15:40 | Discovery of an ApoE4-Targeted Small-Molecule SirT1 Enhancer as a Candidate Drug for the Treatment of Alzheimer’s Disease |
| Varghese John, Mary S. Easton Center for Alzheimer’s Disease Research and Care, University of California Los Angeles, USA | |
| 15:40-16:00 | Advancing dementia screening, care, and research in Kenya: challenges and opportunities |
| David Ndetei, University of Nairobi / Africa Institute of Mental and Brain Health, Kenya | |
| Refreshment Break(16:00-16:10) | |
| Technical session-II | |
| Chairs: Garth D. Ehrlich, Matthew P. Janicki |
|
| 16:10-16:30 | One-week inpatient cognitive behavioral therapy for insomnia: a retrospective study |
| Qifang Li, Tongji university, China | |
| 16:30-16:50 | Hearing Loss &Tinnitus – Reducing the Risk of Cognitive Decline |
| Keith N. Darrow, Worcester State University, USA | |
| 16:50-17:10 | Heterogeneous treatment effects of BCG vaccine on Alzheimer’s disease risk |
| Irfan Chaudhuri, Harvard University, USA | |
| 17:10-17:30 | Blood neurofilament light chain and phospho-Tau 181 in subjects with mild cognitive impairment due to age-related hearing loss |
| M’hammed Aguennouz, University of Messina, Italy | |
| Poster Presentations (17:30 - 18:00) |
|
| PP-1 | In vitro validation of RARβ-M, Ellorarxine, for use in Alzheimers disease |
| Yunxi Zhang, Durham University, UK | |
| PP-2 | Probing Monoclonal Antibody Specificity for Designing Alzheimer's Vaccines |
| Anne-Cathrine Vogt, University of Bern, Switzerland | |
| PP-3 | Concussion-Related Biomarkers in Retired Rugby Players and Implications for Alzheimer’s Disease and ALS Risk: The UK Rugby Health Study |
| Norah Alanazi, Durham University, UK | |
| PP-4 | Slot Available |
| Note: This is a Tentative program, subjects and timings will changes. | |
| Abstract submissions are open now. To schedule your talk in the program please email to: [email protected] | |
| Day-1 Concludes | |
day 2 agenda
| Day -2 (October 02, 2025) | |
| Tentative Program | |
| 08:30-09:00 | Keynote Talk: Safety and immunogenicity of the MultiTEP platform-based Aβ vaccine, AV-1959R, for secondary preventive therapy of individuals with preclinical Alzheimer’s |
| Michael G. Agadjanyan, The Institute for Molecular Medicine, USA | |
| 09:00-09:30 | Keynote Talk: Can we Treat Osteoporosis, Obesity and Neurodegeneration with a Single FSH–Blocking Drug? |
| Mone Zaidi, The Icahn School of Medicine at Mount Sinai, USA | |
| Technical session-III | |
| Chairs: Scott B. Selleck, Amanda J. Myers |
|
| 09:30-09:50 | Short and Long-term Effects of Transcranial Alternating Electrical Stimulation Paired with Cognitive Exercises as a Treatment for Cognitive Impairment |
| Zahra Moussavi, University of Manitoba AND Riverview Health Center, Canada | |
| 09:50-10:10 | Taking care of elderly patients with neurocognitive disorders in Valenciennes’ Hospital Center |
| Anne Desprez & Cartignies Cindy, Centre Hospitalier de Valenciennes, France | |
| Refreshment Break (10:10-10:30) | |
| 10:30-10:50 | Older adults with dementia:knowledge and attitudes of physicians in health units |
| Ana Beatriz Quintes Steiner, UNIFESP, Brazil | |
| 10:50-11:10 | The efficacy of Sham rTMS stimulation |
| Brian Lithgow, University of Manitoba, Canada | |
| 11:10-11:30 | A Proposed Role for Lymphatic Supermicrosurgery in the Management of Alzheimer’s Disease: A Primer for Reconstructive Microsurgeons |
| Joon Pio Hong, Asan Medical Center, University of Ulsan, South Korea | |
| 11:30-11:50 | Bridging the gender gap in mental health: Correlational insights and a sensitive proposal for addressing social isolation in Chilean older people |
| Christine Gierke, University of Chile, Chile | |
| 11:50-12:10 | Evaluation of Sepsis-induced mechanisms driving long-term CNS dysfunction and ADRD risk |
| Gemma Casadesus, University of Florida, USA | |
| 12:10-12:30 | Deep learning-based methods for the early prediction of Alzheimer’s Disease |
| Serdar Bozdag, University of North Texas, USA | |
| 12:30-12:50 | Non-inflammatory outcomes of P. gingilvalis outer membrane vesicles exposure in the embryonic mouse brain |
| Christian L. Lauber, Nationwide Children’s Hospital, USA | |
| Lunch Break @ Restaurant (12:50-13:50) | |
| Technical session-IV | |
| Chair: Charles R Joseph, Michael G. Agadjanyan |
|
| 13:50-14:10 | The Speech Disappears, but the Music Remains |
| Jaana Ruotsalainen, University of Jyväskylä, Finland | |
| 14:10-14:30 | Extracellular Tau and S100A9 proteins induce phagoptosis of live neurons |
| Vilmante Borutaite, Lithuanian University of Health Sciences, Lithunia | |
| 14:30-14:50 | Heparan sulfate modified protein signaling and neurodegenerative disease |
| Scott Selleck, Pennsylvania State University, USA | |
| 14:50-15:10 | Valiltramiprosate Effects on Microstructural Integrity of Grey and White Matter in APOE4/4 Homozygotes with Early AD and their Correlations to Clinical Outcomes: MRI Mean Diffusivity Results from the 78-Week APOLLOE4 Phase 3 Trial |
| Earvin Liang, Alzheon Inc., Framingham, MA, USA | |
| 15:10-15:30 | Maternal and early life exposure induced AD- like pathophysiology |
| Aluru Parithathvi, Manipal School of Life Sciences, India | |
| Refreshment Break(15:30-15:50) | |
| 15:50-16:10 | Semaglutide ameliorates Alzheimer’s disease and restores oxytocin in APP/ PS1 mice and human brain organoid models |
| Zhihui Zhong, West China Hospital, Sichuan University, China | |
| 16:10-16:30 | Dihydromyricetin as a Dual-Target Neuroprotector: Clearing Tau and Aβ for Alzheimer's Disease Intervention |
| Judy Qiao, Towncom International Group, USA | |
| 16:30-16:50 | Genetic and biomarker research on dementia in rural Kenya: insights from the READD-ADSP project |
| Victoria Mutiso, Africa Institute of Mental and Brain Health, Kenya | |
| Day-2 Concludes | |
posters agenda
| Poster Presentations | |
| PP-1 | In vitro validation of RARβ-M, Ellorarxine, for use in Alzheimers disease |
| Yunxi Zhang, Durham University, UK | |
| PP-2 | Probing Monoclonal Antibody Specificity for Designing Alzheimer's Vaccines |
| Anne-Cathrine Vogt, University of Bern, Switzerland | |
| PP-3 | Slot Available |
| PP-4 | Concussion-Related Biomarkers in Retired Rugby Players and Implications for Alzheimer’s Disease and ALS Risk: The UK Rugby Health Study |
| Norah Alanazi, Durham University, UK | |
| PP-5 | FUS-mediated Blood-brain barrier disruption for delivering anti-A? antibodies in 5XFAD Alzheimer’s disease mice |
| Christakis Damianou, Cyprus University of Technology, Cyprus | |
| PP-6 | TBA |
| Sven Meuth, Heinrich-Heine-Universität Düsseldorf, Germany | |
| Abstract submissions are open now. To schedule your talk in the program please email to: [email protected] | |
| Day-2 Concludes | |
posters agenda
| 6th Edition of Innovations and State of the Art in ALZHEIMER'S & DEMENTIA Oct 01 - 02, 2025 at Berlin, Germany (Hybrid Event) |
|
| Day -1 (October 01, 2025) | |
| Virtual Program | |
| 12:30-13:00 | Keynote Talk: Sex-specific brain protection in the clinical scenario: the case of davuentide |
| Illana Gozes, Tel Aviv University, Israel | |
| 13:00-13:20 | From Phenotype Drug Screening to Biological Target identification for Alzheimer’s disease-modifying development |
| SERGEANT Nicolas, University of Lille, France | |
| 13:20-13:40 | Negative Plasticity, Language Impairment and the Role of Artificial Intelligence in Alzheimer’s Disease |
| Erika Smeriglio, University of Messina, Italy | |
| 13:40-14:00 | Enhancing the quality of life for family caregivers of people with Alzheimer's via virtual communities of practice |
| Montse Romero-Mas, University of Vic - Central University of Catalonia, Spain | |
| 14:00-14:20 | Uncovering the mechanistic basis of menopause mediated dementia vulnerability |
| Matthew G Pontifex, University of East Anglia, United Kingdom | |
| 14:20-14:40 | Pre-existing cognitive disorders and Long COVID neurocognitive sequelae: Why Do We Know So Little? |
| Caroline Jose,Vitalité Health Network, Canada | |
| 14:40-15:00 | Sleep Movements and Respiratory Coupling as a Biobehavioral Metric for Early Alzheimer’s Disease |
| Marie J. Hayes, University of Maine, United States | |
| 15:00-15:20 | Successes and Challenges: Insights from the first six months of the CONNECT program |
| Chitrali R. Mamlekar & Melissa A. Alunni, Misericordia University, USA | |
| 15:20-15:40 | Aging as a target for the prevention and treatment of Alzheimer’s disease |
| Raymond Scott Turner, Georgetown University, USA | |
| 15:40-16:00 | Clinicians' Reluctance to Implement a Deeply Demented Patient's Advance Directive: A Broken Moral Compass |
| Norman L. Cantor, Rutgers University School of Law, USA | |
| 16:00-16:20 | Amyloid β fragments that suppress oligomers but not fibrils are cytoprotective |
| Suren A. Tatulian, University of Central Florida, USA | |
| 16:20-16:40 | Futuristic Alzheimer's therapy: acoustic-stimulated piezoelectric nanospheres for amyloid reduction |
| Manju Sharma, University of Georgia, USA | |
| 16:40-17:00 | Combination therapy for neurodegenerative diseases |
| Alexander Shtilbans, Weill Cornell Medicine, USA | |
| 17:00-17:20 | Enhancing Alzheimer's Disease Care Across Veterans Affairs Clinics: A Multi-site Quality Improvement Initiative |
| Arushi Kapoor, University of Pennsylvania, USA | |
| 17:20-17:40 | Association of Plasma Protein Risk Scores for Mild Cognitive Impairment and Alzheimer Disease in the Framingham Heart Study |
| Habbiburr Rehman, Boston University, USA | |
| 17:40-18:00 | Revised Criteria for Diagnosis and Staging of Alzheimer's Disease |
| Clifford R. Jack, Mayo Clinic, USA | |
| 18:00-18:20 | Variational autoencoder latent space as a robust and pragmatic clinical classification tool for neurodegenerative diseases |
| William C. Wakefield, Mayo Clinic, USA | |
| 18:20-18:40 | Efficacy monitoring using amyloid and tau PET neuroimaging in Down syndrome populations |
| Bradley T. Christian, University of Wisconsin-Madison, USA | |
| 18:40-19:00 | Exploring the Relationship Between Aβ and α?Synuclein Pathologies: Longitudinal CSF Analysis and Cognitive Decline in the ADNI |
| Duygu Tosun, University of California - San Francisco, USA | |
| 19:00-19:20 | An integrative review about electrophysiological biomarkers of cognitive impairment in Alzheimer’s disease: A developing relationship |
| Ezra C. Holston, University of Nevada Reno, USA | |
| 19:20-19:40 | Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimer’s disease: a randomized, controlled clinical trial |
| Dean Ornish, Preventive Medicine Research Institute, USA | |
| 19:40-20:00 | Cerebrospinal fluid miRNAs identify sex-dependent alterations in synaptic proteins in humans with Alzheimer’s disease |
| Ursula Sandau, Oregon Health & Science University (OHSU), USA | |
| Day-1 Concludes | |
| Day -2 (October 02, 2025) | |
| Virtual Program | |
| 10:00-10:20 | The vasculature as a therapeutic target for Alzheimer’s disease |
| Jennifer Gamble, Centenary Institute and University of Sydney, Australia | |
| 10:20-10:40 | CareWindow: Enhancing Communication for Seniors and Individuals with Disabilities |
| Zachary Bailey, Care Window, Australia | |
| 10:40-11:00 | Stem Cell-Derived Extracellular Vesicles: A Promising Strategy for Alzheimer's Disease Treatment |
| Qiqi Lyu, Singapore General Hospital, Singapore | |
| 11:00-11:20 | Structural Changes in Cerebral Microvasculature Induced by Ferroptosis Contribute to Blood–Brain Barrier Destruction in Alzheimer's Disease: An Autopsy Study |
| Yuan Cao, Peking Union Medical College Hospital, China | |
| 11:20-11:40 | OXYGEN-OZONE THERAPY AND COGNITIVE FRAILTY: A NONPHARMACOLOGICAL APPROACH TO POTENTIALLY RESOLVE IMMUNE AND INFLAMMATORY DYSFUNCTIONS |
| Antonio Carlo GALOFORO, University of Pavia, Italy | |
| 11:40-12:00 | How do we co-produce care planning with people living with dementia? |
| Inga Stewart, St Andrew's Healthcare, United Kingdom | |
| 12:00-12:20 | From healthy aging to dementia: potential role of DNA methylation |
| Andrea Stoccoro, University of Pisa, Italy | |
| 12:20-12:40 | Second Partnership and Dementia Care in a Blended Family: CaseStudy of a Wicked Problem |
| Olga Asrun Stefansdottir, University of Akureyri, Iceland | |
| 12:40-13:00 | In vitro validation of RARβ-M, Ellorarxine, for use in Alzheimers disease |
| Paul Chazot & Yunxi Zhang, Durham University, UK | |
| 13:00-13:20 | Blood biomarkers for tracking the effects of multidomain interventions in preventing cognitive decline |
| Gessica Sala, University of Milano-Bicocca, Monza, Italy | |
| 13:20-13:40 | Concussion-Related Biomarkers in Retired Rugby Players and Implications for Alzheimer’s Disease and ALS Risk: The UK Rugby Health Study |
| Paul Chazot & Norah Alanazi, Durham University, UK | |
| 13:40-14:00 | High-throughput CRISPR screen of GWAS loci in microglia reveals novel risk genes and pathways for Alzheimer’s and multiple sclerosis |
| Michael D. Gallagher, Whitehead Institute for Biomedical Research, USA | |
| 14:00-14:20 | The Brain Tissue Properties Within the Cerebellum Play Role in Executive Functioning and Memory Performance in Healthy Older Adults |
| Soodeh Moallemian, Rutgers University–Newark, USA | |
| 14:20-14:40 | Gamification and Social Support to Increase Physical Activity among Older Adults at Risk for Alzheimer's Disease and Related Dementias |
| S. Ryan Greysen, University of Pennsylvania School of Medicine, USA | |
| 14:40-15:00 | Supplementation of Seaweed Extracts to the Diet Reduces Symptoms of Alzheimer’s Disease in the APPswePS1ΔE9 mouse model |
|
Monique T Mulder, Erasmus University Medical Center, The Netherlands |
|
| 15:00-15:30 | Keynote Talk: Implementation of plasma p-tau217 in treatment trials: Feasibility and Scalability |
| Leslie M. Shaw, University of Pennsylvania, USA | |
| 15:30-15:50 | A randomized feasibility trial of the modified Atkins diet in older adults with mild cognitive impairment due to Alzheimer’s disease |
| Alison Buchholz, The Johns Hopkins University School of Medicine, USA | |
| 15:50-16:10 | Traumatic Brain Injury Worsens the Inflammatory Response in Mice With a Genetic Predisposition To Alzheimer’s Disease: A Role for Inflammasome Signaling |
| Juan Pablo De Rivero Vaccari, University Miami Miller School of Medicine, USA | |
| 16:10-16:30 | Blood-brain barrier permeability contributes to cognitive impairment in the aftermath of SARS-CoV-2 infection: a role for cerebrovascular Wnt/beta-Catenin and Caveolin-1 |
| Sarah E. Lutz, University of Illinois at Chicago College of Medicine, USA | |
| 16:30-16:50 | miRNA Phase Separation in control of Alzheimer’s Disease |
| Suvendra Bhattacharyya, University of Nebraska Medical Center, USA | |
| 16:50-17:10 | Curcumin and omega-3 fatty acids: nutraceuticals against Alzheimer's disease |
| Velasco-Rodríguez, Luz del C, Universidad Veracruzana, Mexico | |
| 17:10-17:30 | New Language Learning as a Cognitive Intervention in Aging: Behavioral and Neuroimaging Evidence |
| Ladan Ghazi Saidi, University of Nebraska-Lincoln, USA | |
| 17:30-17:50 | Compensate or rehabilitate? SLPs’ current approach to dysphagia in dementia |
| Angela Van Sickle, Texas Tech University Health Sciences Center, USA | |
| 17:50-18:10 | How an energy-redox boost may rescue AD to restore autophagy and remove amyloid |
| Gregory J. Brewer, University of California Irvine, USA | |
| 18:10-18:30 | Enhancing cognitive functioning in dementia through at therapy: A randomized trial based on the Expressive therapies Continuum (ETC) framework |
| Jinnie Jeon, Adler University, Canada | |
| 18:30-18:50 | Inhibition of brain glutamate carboxypeptidase II (GCPII) to enhance cognitive function in HIV |
| Meixiang Huang, Johns Hopkins University, USA | |
| 18:10-18:30 | TBA |
| Day-2 Concludes | |